Kumok Choi
Nurse Practitioner · Los Angeles, CANPI 1225379282
Payments from drug & device makers
Across 111 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$400
- AbbVie$260
- Bayer$248
- Lilly USA, LLC$216
- GSK$159
- Esperion Therapeutics, Inc.$145
- plus $865 from 17 others
What the payments were for
- Food & beverage$2,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $400 |
| AbbVie | 14 | $260 |
| Bayer | 11 | $248 |
| Lilly USA, LLC | 11 | $216 |
| GSK | 7 | $159 |
| Esperion Therapeutics, Inc. | 8 | $145 |
| Ironwood Pharmaceuticals, Inc | 5 | $104 |
| Novartis | 4 | $86 |
| Vivus LLC | 4 | $82 |
| Nestle Healthcare Nutrition Inc. | 4 | $73 |
| Boehringer Ingelheim | 3 | $71 |
| Eisai Inc. | 3 | $68 |
| Astellas Pharma US Inc | 3 | $67 |
| Almatica Pharma LLC | 3 | $63 |
| Scilex Pharmaceuticals Inc. | 3 | $61 |
| Radius Health, Inc. | 2 | $37 |
| Novo Nordisk | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Pfizer | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $16 |
| Merck | 1 | $15 |
How this compares
$2,294 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 16 | $28,185 |
| CreonLipase/Protease/Amylase | 11 | $9,270 |
| Olmesartan Medoxomil | 32 | $330 |
| Atorvastatin Calcium | 45 | $307 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 11 | $284 |
| Losartan Potassium | 19 | $213 |
| Tamsulosin Hcl | 18 | $192 |
| Levothyroxine Sodium | 14 | $189 |
| Metformin Hcl | 15 | $175 |
| Amlodipine Besylate | 24 | $152 |
| Febuxostat | 12 | $82 |
| Escitalopram Oxalate | 13 | $67 |
| Pantoprazole Sodium | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $32 | $28,18516 claims |
| AbbVieCreon | $260 | $9,27011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Los Angeles
- Kristin HorwoodLos Angeles$99K
- Yunying ChenLos Angeles$80K
- Lauren BristowLos Angeles$46K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.